Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

465 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M, Blaise D, Tabrizi R, Garban F, Cassuto JP, Chevalier P, Facon T, Ifrah N, Renaud M, Tilly H, Vernant JP, Kuentz M, Bourhis JH, Bordigoni P, Deconinck E, Lioure B, Socié G, Milpied N; French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Vigouroux S, et al. Among authors: tilly h. Haematologica. 2007 May;92(5):627-34. doi: 10.3324/haematol.10924. Haematologica. 2007. PMID: 17488686 Free article.
Interleukin-2 treatment in lymphoma: a phase II multicenter study.
Gisselbrecht C, Maraninchi D, Pico JL, Milpied N, Coiffier B, Divine M, Tiberghien P, Bosly A, Tilly H, Boulat O, et al. Gisselbrecht C, et al. Among authors: tilly h. Blood. 1994 Apr 15;83(8):2081-5. Blood. 1994. PMID: 8161779 Free article. Clinical Trial.
A multicentric randomised study of alpha 2b interferon (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (Ara-c) in previously untreated patients with Ph+ chronic myelocytic leukemia (CML): preliminary cytogenetic results.
Guilhot F, Abgrall JF, Harousseau JL, Bauters F, Brice P, Dine G, Tilly H, Ifrah N, Cassasus P, Rochant H, et al. Guilhot F, et al. Among authors: tilly h. Leuk Lymphoma. 1993;11 Suppl 1:181-3. doi: 10.3109/10428199309047883. Leuk Lymphoma. 1993. PMID: 8251893 Clinical Trial.
Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.
Gisselbrecht C, Haioun C, Lepage E, Bastion Y, Tilly H, Bosly A, Dupriez B, Marit G, Herbrecht R, Deconinck E, Marolleau JP, Yver A, Dabouz-Harrouche F, Coiffier B, Reyes F. Gisselbrecht C, et al. Among authors: tilly h. Leuk Lymphoma. 1997 Apr;25(3-4):289-300. doi: 10.3109/10428199709114168. Leuk Lymphoma. 1997. PMID: 9168439 Clinical Trial.
Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years.
Bastion Y, Blay JY, Divine M, Brice P, Bordessoule D, Sebban C, Blanc M, Tilly H, Lederlin P, Deconinck E, Salles B, Dumontet C, Brière J, Coiffier B. Bastion Y, et al. Among authors: tilly h. J Clin Oncol. 1997 Aug;15(8):2945-53. doi: 10.1200/JCO.1997.15.8.2945. J Clin Oncol. 1997. PMID: 9256139 Clinical Trial.
465 results